|
|
Volumn 326, Issue 5959, 2009, Pages
|
|
β-Thalassemia treatment succeeds, with a caveat
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA GLOBIN;
HEMOGLOBIN;
HIGH MOBILITY GROUP A2 PROTEIN;
RECOMBINANT DNA;
BETA THALASSEMIA;
BLOOD TRANSFUSION;
BONE MARROW CELL;
BONE MARROW TRANSPLANTATION;
ERYTHROCYTE;
GENE INSERTION;
GENE THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
LENTIVIRINAE;
NOTE;
OXYGEN TRANSPORT;
PRIORITY JOURNAL;
SICKLE CELL ANEMIA;
ADULT;
BIOSYNTHESIS;
CELL PROLIFERATION;
CLINICAL TRIAL;
GENE VECTOR;
GENETICS;
MALE;
UNITED STATES;
BETA-GLOBINS;
BETA-THALASSEMIA;
CELL PROLIFERATION;
CLINICAL TRIALS AS TOPIC;
GENE THERAPY;
GENETIC VECTORS;
HEMOGLOBINS;
HMGA2 PROTEIN;
HUMANS;
MALE;
UNITED STATES;
YOUNG ADULT;
|
|
EID: 72149123930
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.326.5959.1468-b Document Type: Note |
|
Times cited : (41)
|
|
References (0)
|